阿利吉仑：首款用于治疗高血压的直接肾素抑制剂。

Aliskiren: the first direct renin inhibitor for hypertension.

作者信息

van den Meiracker Anton H, Jan Danser A H

机构信息

Division of Vascular Pharmacology and Metabolism, Room EE1418b, Department of Internal Medicine, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, Netherlands.

出版信息

Curr Cardiol Rep. 2007 Nov;9(6):470-6. doi: 10.1007/BF02938391.

DOI:10.1007/BF02938391

PMID:17999872

Abstract

Aliskiren is the first member of a novel class of antihypertensive agents, the renin inhibitors, that has been approved by the US Food and Drug Administration for the treatment of hypertension. This review discusses its potential differences compared with existing renin-angiotensin-aldosterone system blockers, focusing also on the inactive precursor of renin, prorenin, and the recently discovered (pro)renin receptor. The review summarizes the findings from all clinical trials with aliskiren published so far, and provides an overview of the safety and tolerability of the new drug.

摘要

阿利吉仑是一类新型抗高血压药物（肾素抑制剂）中的首个成员，已获美国食品药品监督管理局批准用于治疗高血压。本综述讨论了它与现有肾素 - 血管紧张素 - 醛固酮系统阻滞剂相比可能存在的差异，同时也关注肾素的无活性前体——肾素原，以及最近发现的（前）肾素受体。该综述总结了迄今为止已发表的所有关于阿利吉仑的临床试验结果，并概述了这种新药的安全性和耐受性。